The use of recombinant thyrotropin in the follow-up of patients with differentiated thyroid cancer

被引:5
作者
Basaria, M
Graf, H
Cooper, DS
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Fed Parana, Hosp Clin, Serv Endocrinol & Metabol Parana, SEMPR, BR-80060000 Curitiba, Parana, Brazil
[3] Sinai Hosp, Div Endocrinol & Metab, Baltimore, MD 21215 USA
关键词
D O I
10.1016/S0002-9343(02)01120-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many clinicians care for patients who have been treated for differentiated thyroid cancer. Recombinant thyrotropin, which stimulates iodine uptake in thyroid tissue, is a safe and effective diagnostic agent for those patients who require radioiodine scanning for routine follow-up. The combination of a whole body radioiodine scan and a serum thyroglobulin measurement can identify virtually all patients with distant metastatic disease. A serum thyroglobulin >2 ng/mL and/or a positive whole body scan after recombinant thyrotropin stimulation suggest residual thyroid tissue or neoplastic disease. The use of recombinant thyrotropin has fewer adverse effects than does the alternative, which is withdrawal of thyroid hormone replacement, although nausea and headache have been reported. However, recombinant thyrotropin is expensive. (C) 2002 by Excerpta Medica, Inc.
引用
收藏
页码:721 / 725
页数:5
相关论文
共 39 条
[11]   RECOMBINANT HUMAN THYROID-STIMULATING HORMONE - INITIAL BIOACTIVITY ASSESSMENT USING HUMAN FETAL THYROID-CELLS [J].
HUBER, GK ;
FONG, P ;
CONCEPCION, ES ;
DAVIES, TF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (06) :1328-1331
[12]   Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma [J].
Ladenson, PW ;
Braverman, LE ;
Mazzaferri, EL ;
BruckerDavis, F ;
Cooper, DS ;
Garber, JR ;
Wondisford, FE ;
Davies, TF ;
DeGroot, LJ ;
Daniels, GH ;
Ross, DS ;
Weintraub, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :888-896
[13]   Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma [J].
Ladenson, PW .
SEMINARS IN NUCLEAR MEDICINE, 2000, 30 (02) :98-106
[14]   Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH [J].
Lippi, F ;
Capezzone, M ;
Angelini, F ;
Taddei, D ;
Molinaro, E ;
Pinchera, A ;
Pacini, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 144 (01) :5-11
[15]   Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma [J].
Luster, M ;
Lassmann, M ;
Haenscheid, H ;
Michalowski, U ;
Incerti, C ;
Reiners, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3640-3645
[16]   Exacerbation of renal failure due to hypothyroidism in a patient with ischemic nephropathy [J].
Makino, Y ;
Fujii, T ;
Kuroda, S ;
Inenaga, T ;
Kawano, Y ;
Takishita, S .
NEPHRON, 2000, 84 (03) :267-269
[17]   Papillary thyroid carcinoma metastatic to the pituitary gland [J].
Masiukiewicz, US ;
Nakchbandi, IA ;
Stewart, AF ;
Inzucchi, SE .
THYROID, 1999, 9 (10) :1023-1027
[18]   Detection of residual and recurrent thyroid cancer by radionuclide imaging [J].
Maxon, HR .
THYROID, 1999, 9 (05) :443-446
[19]  
Mazzaferri EL, 1999, ONCOLOGY-NY, V13, P391
[20]   LONG-TERM IMPACT OF INITIAL SURGICAL AND MEDICAL THERAPY ON PAPILLARY AND FOLLICULAR THYROID-CANCER [J].
MAZZAFERRI, EL ;
JHIANG, SM .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 (05) :418-428